MetaCap

BeyondSpring (BYSI) vs Tvardi Therapeutics (TVRD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tvardi Therapeutics (TVRD) has outperformed BeyondSpring (BYSI) over the past year, losing 74.8% versus a loss of 82.8%. Over five years, BYSI leads with a -97.7% price change compared with -99.8% for TVRD. BeyondSpring is the larger company by market cap ($13.7 million vs $13.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BYSI-82.77%TVRD-74.76%
+33%-28%-88%
Nov 21, 20251 yearNov 20, 2026
BYSI-97.51%TVRD-99.81%
+14%-46%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BYSI versus TVRD key metrics
MetricBYSITVRD
Share price$0.33$0.9893
Market cap$13.66M$13.22M
1-day change-24.49%+4.57%
YTD return-79.75%-76.99%
1-year return-82.77%-74.76%
5-year return-97.70%-99.79%
EPS (TTM)$-0.20$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-1.01M$-18.21M
52-week high$2.44$5.69
52-week low$0.299$0.773
Distance from 52-week high-86.48%-82.61%
Analyst consensus—buy
Avg. price target upside—+835.00%
Average volume261.79K235.95K
Shares outstanding41.41M13.36M
Employees4412
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Tvardi Therapeutics

TVRD stock →

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

BYSI vs TVRD FAQ

Which is bigger, BeyondSpring or Tvardi Therapeutics?

BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $13.22M for Tvardi Therapeutics (TVRD).

Which stock has performed better over the past year, BYSI or TVRD?

TVRD returned -74.76% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.

Are BeyondSpring and Tvardi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons